Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(2):215–220. doi: 10.1038/bjc.1998.467

Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours.

J E Nutt 1, J K Mellon 1, K Qureshi 1, J Lunec 1
PMCID: PMC2062898  PMID: 9683296

Abstract

The matrix metalloproteinases are a family of enzymes that degrade the extracellular matrix and are considered to be important in tumour invasion and metastasis. The effect of epidermal growth factor (EGF) on matrix metalloproteinase-1 (MMP1) production in two human bladder tumour cell lines, RT112 and RT4, has been investigated. In the RT112 cell line, an increase in MMP1 mRNA levels was found after a 6-h incubation with EGF, and this further increased to 20-fold that of control levels at 24- and 48-h treatment with 50 ng ml(-1) of EGF. MMP2 mRNA levels remained constant over this time period, whereas in the RT4 cells no MMP2 transcripts were detectable, but MMP1 transcripts again increased with 24- and 48-h treatment with 50 ng ml(-1) of EGF. MMP1 protein concentration in the conditioned medium from both cell lines increased with 24- and 48-h treatment of the cells and the total MMP1 was higher in the medium than the cells, demonstrating that the bladder tumour cell lines synthesize and secrete MMP1 protein after continuous stimulation with EGF. MMP1 protein was detected in urine from patients with bladder tumours, with a significant increase in concentration with increased stage and grade of tumour. MMP1 urine concentrations may therefore be a useful prognostic indicator for bladder tumour progression.

Full text

PDF
215

Images in this article

216Figure 1
on p.216
217Figure 2
on p.217

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angel P., Baumann I., Stein B., Delius H., Rahmsdorf H. J., Herrlich P. 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region. Mol Cell Biol. 1987 Jun;7(6):2256–2266. doi: 10.1128/mcb.7.6.2256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benbow U., Brinckerhoff C. E. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol. 1997 Mar;15(8-9):519–526. doi: 10.1016/s0945-053x(97)90026-3. [DOI] [PubMed] [Google Scholar]
  3. Brotherick I., Lennard T. W., Wilkinson S. E., Cook S., Angus B., Shenton B. K. Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay. Cytometry. 1994 Jul 1;16(3):262–269. doi: 10.1002/cyto.990160311. [DOI] [PubMed] [Google Scholar]
  4. Church G. M., Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A. 1984 Apr;81(7):1991–1995. doi: 10.1073/pnas.81.7.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clifford S. C., Thomas D. J., Neal D. E., Lunec J. Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. Br J Cancer. 1994 Apr;69(4):680–686. doi: 10.1038/bjc.1994.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davies B., Waxman J., Wasan H., Abel P., Williams G., Krausz T., Neal D., Thomas D., Hanby A., Balkwill F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993 Nov 15;53(22):5365–5369. [PubMed] [Google Scholar]
  7. Edwards D. R., Murphy G., Reynolds J. J., Whitham S. E., Docherty A. J., Angel P., Heath J. K. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987 Jul;6(7):1899–1904. doi: 10.1002/j.1460-2075.1987.tb02449.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  9. Fisher D. A., Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev. 1990 Aug;11(3):418–442. doi: 10.1210/edrv-11-3-418. [DOI] [PubMed] [Google Scholar]
  10. Fuse H., Mizuno I., Sakamoto M., Katayama T. Epidermal growth factor in urine from the patients with urothelial tumors. Urol Int. 1992;48(3):261–264. doi: 10.1159/000282347. [DOI] [PubMed] [Google Scholar]
  11. Gohji K., Fujimoto N., Komiyama T., Fujii A., Ohkawa J., Kamidono S., Nakajima M. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer. 1996 Dec 1;78(11):2379–2387. [PubMed] [Google Scholar]
  12. Greene J., Wang M., Liu Y. E., Raymond L. A., Rosen C., Shi Y. E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 1996 Nov 29;271(48):30375–30380. doi: 10.1074/jbc.271.48.30375. [DOI] [PubMed] [Google Scholar]
  13. Grignon D. J., Sakr W., Toth M., Ravery V., Angulo J., Shamsa F., Pontes J. E., Crissman J. C., Fridman R. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 1996 Apr 1;56(7):1654–1659. [PubMed] [Google Scholar]
  14. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991 Jan 25;64(2):327–336. doi: 10.1016/0092-8674(91)90642-c. [DOI] [PubMed] [Google Scholar]
  15. Lipponen P., Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994 Jun;69(6):1120–1125. doi: 10.1038/bjc.1994.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Margulies I. M., Höyhtyä M., Evans C., Stracke M. L., Liotta L. A., Stetler-Stevenson W. G. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):467–474. [PubMed] [Google Scholar]
  17. Matrisian L. M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990 Apr;6(4):121–125. doi: 10.1016/0168-9525(90)90126-q. [DOI] [PubMed] [Google Scholar]
  18. McDonnell S. E., Kerr L. D., Matrisian L. M. Epidermal growth factor stimulation of stromelysin mRNA in rat fibroblasts requires induction of proto-oncogenes c-fos and c-jun and activation of protein kinase C. Mol Cell Biol. 1990 Aug;10(8):4284–4293. doi: 10.1128/mcb.10.8.4284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mellon K., Wright C., Kelly P., Horne C. H., Neal D. E. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol. 1995 Mar;153(3 Pt 2):919–925. [PubMed] [Google Scholar]
  20. Muller D., Wolf C., Abecassis J., Millon R., Engelmann A., Bronner G., Rouyer N., Rio M. C., Eber M., Methlin G. Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res. 1993 Jan 1;53(1):165–169. [PubMed] [Google Scholar]
  21. Murray G. I., Duncan M. E., O'Neil P., Melvin W. T., Fothergill J. E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996 Apr;2(4):461–462. doi: 10.1038/nm0496–461. [DOI] [PubMed] [Google Scholar]
  22. Nakagawa T., Kubota T., Kabuto M., Sato K., Kawano H., Hayakawa T., Okada Y. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg. 1994 Jul;81(1):69–77. doi: 10.3171/jns.1994.81.1.0069. [DOI] [PubMed] [Google Scholar]
  23. Naruo S., Kanayama H., Aki M., Kagawa S. [Gene expressions of type IV collagenase and tissue inhibitor of metalloproteinases (TIMP) in human bladder cancers]. Nihon Hinyokika Gakkai Zasshi. 1993 May;84(5):841–850. doi: 10.5980/jpnjurol1989.84.841. [DOI] [PubMed] [Google Scholar]
  24. Naruo S., Kanayama H., Takigawa H., Kagawa S., Yamashita K., Hayakawa T. Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int J Urol. 1994 Sep;1(3):228–231. doi: 10.1111/j.1442-2042.1994.tb00040.x. [DOI] [PubMed] [Google Scholar]
  25. Nomura H., Fujimoto N., Seiki M., Mai M., Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer. 1996 Feb 20;69(1):9–16. doi: 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  26. Nutt J. E., Harris A. L., Lunec J. Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells. Br J Cancer. 1991 Oct;64(4):671–676. doi: 10.1038/bjc.1991.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nutt J. E., Lunec J. Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells. Eur J Cancer. 1996 Nov;32A(12):2127–2135. doi: 10.1016/s0959-8049(96)00261-4. [DOI] [PubMed] [Google Scholar]
  28. Powell W. C., Matrisian L. M. Complex roles of matrix metalloproteinases in tumor progression. Curr Top Microbiol Immunol. 1996;213(Pt 1):1–21. doi: 10.1007/978-3-642-61107-0_1. [DOI] [PubMed] [Google Scholar]
  29. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994 Jul 7;370(6484):61–65. doi: 10.1038/370061a0. [DOI] [PubMed] [Google Scholar]
  30. Shibata T., Kawano T., Nagayasu H., Okumura K., Arisue M., Hamada J., Takeichi N., Hosokawa M. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol. 1996;17(3):168–175. doi: 10.1159/000217979. [DOI] [PubMed] [Google Scholar]
  31. Stetler-Stevenson W. G., Hewitt R., Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996 Jun;7(3):147–154. doi: 10.1006/scbi.1996.0020. [DOI] [PubMed] [Google Scholar]
  32. Urbanski S. J., Edwards D. R., Maitland A., Leco K. J., Watson A., Kossakowska A. E. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer. 1992 Dec;66(6):1188–1194. doi: 10.1038/bjc.1992.434. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES